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Abstract
Many patients with ischaemic heart disease also have diabetes. As myocardial infarction is a major cause of mortality and morbidity in these
patients, treatments that increase cell survival in response to ischaemia and reperfusion are needed. Exosomes—nano-sized, lipid vesicles
released from cells—can protect the hearts of non-diabetic rats. We previously showed that exosomal HSP70 activates a cardioprotective sig-
nalling pathway in cardiomyocytes culminating in ERK1/2 and HSP27 phosphorylation. Here, we investigated whether the exosomal cardiopro-
tective pathway remains intact in the setting of type II diabetes. Exosomes were isolated by differential centrifugation from non-diabetic and
type II diabetic patients, from non-diabetic and Goto Kakizaki type II diabetic rats, and from normoglycaemic and hyperglycaemic endothelial
cells. Exosome size and number were not significantly altered by diabetes. CD81 and HSP70 exosome markers were increased in diabetic rat
exosomes. However, exosomes from diabetic rats no longer activated the ERK1/2 and HSP27 cardioprotective pathway and were no longer pro-
tective in a primary rat cardiomyocytes model of hypoxia and reoxygenation injury. Hyperglycaemic culture conditions were sufficient to impair
protection by endothelial exosomes. Importantly, however, exosomes from non-diabetic rats retained the ability to protect cardiomyocytes from
diabetic rats. Exosomes from diabetic plasma have lost the ability to protect cardiomyocytes, but protection can be restored with exosomes
from non-diabetic plasma. These results support the concept that exosomes may be used to protect cardiomyocytes against ischaemia and
reperfusion injury, even in the setting of type II diabetes.
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Introduction
Myocardial ischaemia and reperfusion (IR) injury are a major cause of
cell death in patients who experience a myocardial infarction. As the
majority of myocytes are terminally differentiated and unable to prolif-
erate, treatments that increase cell survival after infarction would be
of great clinical benefit. However, many patients with ischaemic heart
disease also have diabetes. In the USA, the occurrence of diabetes in
patients undergoing isolated primary coronary artery bypass grafting
increased from 33% to 40% between 2000 and 2009 [1]. The pres-
ence of diabetes can impair cardioprotective strategies and worsen
outcome [2, 3]. For example, the incidence of death or re-infarction
after acute coronary syndromes is significantly higher in patients who
have diabetes compared with those who do not [4]. This illustrates
the need for cardioprotective treatments that are effective in the set-
ting of diabetes.
Exosomes are nano-sized, lipid bilayer vesicles able to communi-
cate signals between cells [5–8]. They are defined as ~100 nm diam-
eter derivatives of the endosomal compartment [7]. We previously
showed that plasma exosomes can protect the hearts of rats from IR
injury, both in vitro and in vivo [9]. Furthermore, exosomes directly
protected primary cardiomyocytes against injury in an experimental
model simulating IR in vitro [9]. The mechanism of protection
involved HSP70 on the exosomal surface, which stimulated toll-like
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receptor 4 (TLR4) receptors on cardiomyocytes. This led to the acti-
vation of ERK1/2 and p38 MAPK, kinases previously identified as part
of the reperfusion injury salvage kinase (RISK) pathway of cardiopro-
tection [10, 11]. P38 MAPK subsequently phosphorylated HSP27, a
member of the highly cytoprotective family of small heat shock pro-
teins [9]. As clinical trials commence using exosomes in a variety of
disease settings (primarily cancer to date, but with other fields pro-
gressing rapidly [7]), it is vital to understand the biological capabili-
ties of exosomes and their signalling pathways.
Here, in order to further our investigations into exosomes as
potential treatments for myocardial IR injury, we investigated plasma
exosomes from Goto Kakizaki (GK) rats with type II diabetes and found
they have lost the ability to active cardioprotective signalling path-
ways. Although exosomes from non-diabetic rats or humans reduced
cell death in cardiomyocytes subject to hypoxia and reoxygenation,
those from diabetic individuals were no longer able to do so. Plasma
exosomes originate from various sources [12] including endothelium,
muscle, platelets, leucocytes and erythrocytes. We isolated exosomes
from primary endothelial cells (HUVECs) and showed they can protect
cardiomyocytes against hypoxia and reoxygenation. Although hyper-
glycaemic culture did not alter rates of exosome production or exoso-
mal morphology, it eliminated their cardioprotective ability. However,
we found no evidence that hyperglycaemia alters exosomal HSP70
levels, or that glycation of HSP70 renders it incapable of inducing pro-
tection. Lastly, in order to investigate their potential for therapeutic
application, we investigated whether exosomes from non-diabetic
individuals are able to protect cells from diabetic hearts.
Materials and methods
All human and animal studies were approved by the appropriate institu-
tional review boards. Animals were treated in accordance with the Ani-
mals (Scientific Procedures) act 1986 published by the UK Home Office
and the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (revised 2011). The study of human
samples was performed according to ethics approval reference 13/LO/
0222 and Declaration of Helsinki principles.
Animals
Male GK or Wistar rats (aged circa 4 months, 250–300 g) were
obtained from Charles River, United Kingdom. Animals were treated in
accordance with the Animals (Scientific Procedures) act 1986 published
by the UK. Home Office and the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of Health (Publica-
tion No. 85-23, revised 1996).
Primary cardiomyocyte isolation and hypoxia-
reoxygenation studies
Adult rats were anaesthetized with 200 mg/kg i.p. Na-pentobarbital, the
hearts were isolated and perfused via the aorta. Cardiomyocytes were
isolated by collagenase II perfusion using a standard method and plated
on laminin in 6-well tissue-culture plates [11]. Cells were subject to
hypoxia and reoxygenation with a buffer simulating the ischaemic milieu
containing 128 mM NaCl, 2.2 mM NaHCO3, 14.8 mM KCl, 1.2 mM
MgSO4, 1.2 mM K2HPO4, 1 mM CaCl2, 10 mM Na-lactate (pH 6.4) in a
hypoxic chamber containing 95% N2/ 5% CO2 for 3 hrs, after which
cells were placed in a standard incubator in normal medium for 1 hr.
The percentage cell death was determined by staining dead cells with
propidium iodide and counting cells in three separate fields per well
(i.e. 100–150 cells per group per experiment). Control cells were incu-
bated in normoxic medium 118 mM NaCl, 22 mM NaHCO3, 2.6 mM
KCl, 1.2 mM MgSO4, 1.2 mM K2HPO4, 1 mM CaCl2, 10 mM glucose
(pH 7.4 gassed with 95% O2 / 5% CO2). Cardiomyocytes were treated
with 108/ml (0.1 lg) plasma exosomes or 1 ng/ml endotoxin-free
recombinant HSP70 (Enzo Life Sciences, Exeter, UK), and incubated for
30 min. prior to ischaemia. Samples of HSP70 were pre-incubated for
7 days, 37°C in 20 mM glucose, mannitol or methylglyoxal. TAK-242
was used at 5 lM. As a positive control, the cardioprotective agent
insulin (100 nM) was added at reoxygenation.
Rat exosome preparation
Rats were anaesthetized with 200 mg/kg Na-pentobarbital i.p. and
placed on a heated mat. After thoracotomy, 4 ml blood was rapidly
removed into a citrated vaccutainerTM to minimize platelet activation.
Exosomes were prepared by standard differential centrifugation as fol-
lows: centrifugation at 1600 9 g 20 min. RT to obtain plasma, then at
10,000 9 g 30 min. RT to remove cells and platelets, then twice at
100,000 9 g 60 min., 4°C with an MLA-55 rotor, washing with Ca2+
and Mg2+ free PBS [9, 13]. The vehicle control consisted of PBS alone.
Human exosome preparation
After written consent, exosomes were isolated from patients scheduled
to undergo cardiac bypass surgery, aged 50–84 years, with or without
Type II diabetes. Sixty microliters blood was drawn from the antecubital
vein by butterfly syringe into citrated vaccutainersTM (BD Biosciences,
Oxford, UK). The first two vaccutainers were excluded from the exo-
some isolation procedure to avoid artefacts due to platelet activation.
The blood was centrifuged 20 min. at 1600 9 g, RT, to obtain plasma,
which was then centrifuged 30 min. at 10,000 9 g, RT to remove pla-
telets. The supernatant was ultracentrifuged three times (for 90, 60,
then 60 min.) at 100,000 9 g, 4°C, and washed with Ca2+ and Mg2+
free PBS, to pellet exosomes [9, 13].
Cell culture
HUVEC-pooled cells were obtained from Lonza and cultured in EGM-2
BulletKit (Lonza, Slough, UK) for up to 20 population doublings, accord-
ing to the manufacturer’s instructions. To prepare exosomes from cul-
tured endothelial cells, medium was washed and replaced with medium
containing FCS that had been pre-cleared of exosomes by ultracentrifu-
gation for 20 hrs at 100,000 g, 4°C. The absence of exosomes was ver-
ified by NTA. For hyperglycaemic culture, 14.5 mM glucose was added
to bring the total concentration to 20 mM. To control for effects due to
molarity, 14.5 mM mannitol was added to separately cultured cells.
Cells were cultured for 24 hrs before harvesting the medium and
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isolating exosomes using the ultracentrifugation method described
above for rat plasma. Cardiomyocytes were treated with 107/ml HUVEC
exosomes for 30 min. before exposure to hypoxia and reoxygenation.
Electron microscopy
Electron microscopy was performed on a Joel 1010 transmission elec-
tron microscope (Joel Ltd, Warwickshire, UK) after a standard staining
procedure with 0.5% uranyl acetate [13]. Diameter was calculated from
5 to 15 images containing 100–200 vesicles.
Nanoparticle tracking analysis
Concentration and size of exosomes were determined the using a Nano-
sight LM10-HS (Nanosight Ltd, Malvern, UK) as described [9] with con-
stant flow injection. The same dilution was used for all the samples for
consistency. Three recordings of 30 sec. each were captured and anal-
ysed, and the data from at least 1500–3000 individual particle tracks
were analysed per sample.
DELFIA protein quantification
Exosome proteins were quantified using a previously validated dissocia-
tion-enhanced lanthanide fluorescence immunoassay (DELFIA) [14].
Briefly, 5–10 ll of each sample was diluted to 100 ll in PBS, added to
high-binding ELISA plates, and then incubated overnight at 4°C. The
plates were washed three times with DELFIA wash buffer (PerkinElmer,
Cambridge, UK). Wells were blocked with 100 ll 1% BSA in PBS for
1 hr at room temperature, and then washed three times. Primary anti-
bodies (CD81 clone JS-81; HSP70 clone N27F3-4) were added at 1 lg/
ml and plates incubated 2 hrs at room temperature. After washing three
times, goat anti-rabbit IgG or goat anti-mouse IgG1 was added (1:2000
in blocking buffer), and incubated 1 hr at room temperature. Plates
were washed three times, and 1:1000 streptavidin–Europium conjugate
in DELFIA Assay Buffer (PerkinElmer) was added and incubated 1 hr.
Finally, after six washes, 100 ll of the DELFIA Enhancement Solution
was added, and the plate was shaken 2 9 5 min. on the plate reader.
Time-resolved fluorimetry was performed using a Pherastar plate reader
(BMG Labtech, Aylesbury, UK), with excitation of 337 nm, detection at
620 nm, integration time set at 200 ls and lag time of 60 ls.
Flow cytometry
Expression of surface marker molecules was measured using a stan-
dard protocol in which exosomes were bound to aldehyde microspheres
of 4 lm with some modifications [13]. Briefly, macromolecular IgG
complexes were cleared from 2 9 109 exosomes (quantified by NTA)
by an immunoprecipitation pre-clearing protocol using G protein sephar-
ose (Protein G sepharose; GE Healthcare, Chicago, Illinois, USA). Exo-
somes were then bound to 5 ll of aldehyde/sulphate latex
microspheres (4% w/v, 4 lm Molecular Probes, Thermofisher Scienti-
fic, Waltham, MA USA) (a ratio of ~330 exosomes per microsphere), in
1 ml of sterile PBS with agitation at 4°C. Exosome-coated microspheres
were blocked with 3% fatty acid-free BSA for 1 hr at 4°C, then
incubated with isotype control or specific primary antibody against
HSP70, cmHsp70.1-FITC [15]. For the analysis of cells or microspheres,
we used singlet-gated events on SSC/pulse-width. All samples were
analysed using an Accuri C6 flow cytometer (BD Biosciences).
Western blot analyses
For signalling experiments, 108 exosomes/ml were added to cardiomy-
ocyte cultures acutely for 5 min., as indicated, then the cells were
rapidly washed in cold PBS and lysed on ice in a buffer containing
100 mM NaCl, 10 mM Tris (pH 7.6), 1 mM EDTA (pH 8.0), 2 mM
sodium pyrophosphate, 2 mM sodium fluoride, 2 mM b-glyceropho-
sphate and a protease inhibitor cocktail. Where indicated, exosomes
were pre-incubated with antibodies (cmHsp70.1) for 30 min. at a ratio
of 1 lg antibody per 5 lg exosomes. 100 nM insulin was used as a
positive control for Akt phosphorylation. The protein concentration of
cell lysates was determined by BCA assay (Pierce, Thermofisher Scienti-
fic, Waltham, MA USA) and after addition of 20 lg protein per well sep-
arated on a 10% SDS-PAGE gel. Proteins were transferred to
nitrocellulose membranes and were probed using primary antibodies
from Abcam (Milton, Cambridge, UK): antibody 3C to argpyrimidine;
Cell Signalling Technologies (Boston, MA, USA): ERK1/2 (#9102), Phos-
pho-ERK1/2 (Thr202/Tyr204) (#9101), Akt (#9272), Phospho-Akt
(Ser473) (#9271), phospho Hsp27 Ser-82(#12594); and Santa Cruz
Biotechnology (Dallas, Texas, USA): beta-actin (#47778); followed by
fluorescent secondary antibodies, and detection using the Li-cor Odys-
sey at an intensity set to avoid any saturation of bands. The ratio of
phosphorylated Erk1/2 to total Erk1/2 was calculated, and phospho-
HSP27 was measured relative to beta-actin as a loading control.
Statistical analysis
Data are shown as mean  S.E.M. Pairwise comparisons were made
by Student’s t-test. One-way ANOVA was followed by post-test analysis
using the Tukey test for multiple comparisons. Repeated measures
ANOVA was used when replicate cell cultures or primary cell isolates were
treated under each of the conditions, followed by Tukey test. Exosomes
size distributions were compared using a Mann–Whitney U-test or
Kruskal–Wallis test for 2 or 3 groups respectively. P < 0.05 was con-
sidered significant. Degrees of significance were indicated as follows:
*P < 0.05, **P < 0.01, ***P < 0.001.
Results
Exosomes were isolated from normoglycaemic rats (fasting blood glu-
cose 5–6 mM) or from hyperglycaemic GK rats with type II diabetes
(fasting blood glucose 8–12 mM). Exosomes were also isolated from
patients undergoing cardiac surgery who were either non-diabetic or
who were known to have established type II diabetes. Exosomes were
also isolated from HUVECs cultured in hyperglycaemic culture condi-
tions (20 mM glucose) or normoglycaemic conditions (5.5 mM glu-
cose with addition of 14.5 mM mannitol to control for osmolarity).
Exosomes were quantified and characterized by nanoparticle
tracking analysis (NTA) (Fig. 1A–I). The concentration of exosomes
was 1.2  0.4 9 1010/ml in non-diabetic rats and was not
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significantly different in diabetic rats (P = 0.4, N = 5; Fig. 1A). There
was no difference in protein quantity per exosome between non-
diabetic and diabetic rat samples (Fig. S1). The concentration of exo-
somes was 5.8  1.0 9 1012/ml in non-diabetic humans and was
not significantly different in diabetic humans (P = 0.7, N = 3;
Fig. 1D). The concentration of exosomes isolated from normogly-
caemic HUVECs was 8.4  1.5 9 109/ml. The concentration of exo-
somes in replicate dishes cultured in hyperglycaemic conditions, or
under iso-osmotic control conditions was not significantly different
(P = 0.3, N = 8; Fig. 1G). The modal size of isolated vesicles was
~100 nm as expected for a population consisting predominantly of
exosomes and was not significantly different between diabetic and
non-diabetic rats or humans, or between normoglycaemic and hyper-
glycaemic cell cultures (Fig. 1B, E, H).
The identity of the isolated vesicles as exosomes was confirmed by
transmission electron microscopy. Exosomes isolated from each of the
conditions appeared similar in terms of morphology and size
(Fig. 2A–G). Histograms of exosome size distribution (Fig. 2H–J) sug-
gested there might be a slight increase in the size of exosomes from
diabetic rats and humans, but this was found not to be significant.
The identity of the exosomes was confirmed by measuring the
presence of exosome markers CD81, a tetraspanin, and HSP70, using
Fig. 1 The concentration and modal size
of exosome preparations as determined
by Nanoparticle tracking analysis. The
concentration (A) and size (B and C) of
exosomes isolated from non-diabetic rats
and GK diabetic rats. N = 5 per group.
The concentration (D) and size (E and F)
of exosomes isolated from patients with
or without type 2 diabetes. N = 3 per
group. The effect of hyperglycaemic con-
ditions (20 mM Glucose), or iso-osmotic
control conditions (20 mM Mannitol),
compared to normoglycaemic conditions
(4.5 mM Glucose), on the concentration
of exosomes isolated from HUVECs (G),
and their average size (H and I). N = 8
per group. Statistical comparison was by
t-test (A and D), or repeated measures
ANOVA performed on the raw concentration
values (G).
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an ELISA-based assay. HSP70 protein is present in exosomal surface
membrane and is commonly used as a marker of exosomes. A signifi-
cant increase in CD81 and HSP70 levels measured in exosomes iso-
lated from diabetic rats (Fig. 3A and B). HUVEC exosomes contained
CD81 (Fig. 3C), although interestingly HSP70 was undetectable in
HUVEC exosomes. The levels of CD81 were unchanged by exposure
to high glucose or mannitol (Fig. 3C).
We previously used a neutralizing antibody to HSP70
(cmHsp70.1) to demonstrate that HSP70 localized on the surface of
exosomes induces cardioprotection by signalling to TLR4 [9]. Using a
flow cytometry-based assay we found that surface levels of the pro-
tective HSP70 epitope were not significantly different between exo-
somes isolated from non-diabetic and diabetic rats (Fig. 3D).
To compare cardioprotection by exosomes from normoglycaemic
and diabetic samples, a cell-based model simulating IR was used. Pri-
mary adult rat cardiomyocytes were isolated and pre-treated for
30 min. with 108/ml exosomes (determined by NTA) isolated from non-
diabetic or diabetic rats, before exposure to 3 hrs hypoxia and 1 hr
reoxygenation. In normoxic cell cultures, cell death varied between 10%
and 20% (Fig. 4A–C, Fig. S2–S4). Hypoxia and reoxygenation increased
cell death significantly to 51  3% (P < 0.001; Fig. 4A). Insulin was
used as a positive control because it provides strong, reproducible pro-
tection in this model [11] and was shown to reduce cell death signifi-
cantly to 26  4% (P < 0.001; Fig. 4A). Exosomes from non-diabetic
rats were also cardioprotective in this model, as expected, and reduced
cell death to 33  5% (P < 0.01) (Fig. 4A). In contrast, exosomes iso-
lated from GK rats were not cardioprotective, and resulted in 48  4%
cell death after hypoxia and reoxygenation (N = 5; Fig. 4A).
In separate experiments, exosomes isolated from patients with
type II diabetes were also unable to protect primary cardiomyocytes
cells from hypoxia and reoxygenation injury (cell death 50  8%,
despite exosomes from non-diabetic human blood reducing cell death
from 54  9% to 29  2% (P < 0.05; Fig. 4B), in line with previous
results [9].
We investigated whether the exosomes produced by endothelial
cells were equally as protective in this model. Exposure of
Fig. 2 Transmission electron microscopy (TEM) of exosomes isolated from the blood of rats (A and B), human patients (C and D) or from cultured
HUVECs under the cultured conditions indicated (E–G). Bar = 100 nm. (H–J) Size distribution diameters from TEM images of vesicles from rats (H)
(N = 399 and 505), humans (I) (N = 297 and 284) and HUVECs (J) (N = 59, 294 and 131). No significant difference was found when distributions
were compared by Mann–Whitney U-test or Kruskal–Wallis test for 2 or 3 groups, respectively.
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cardiomyocytes to exosomes produced by HUVECs reduced cell
death caused by hypoxia and reoxygenation from 39  4% to
24  3% (P < 0.001; Fig. 4C). Diabetes is a complex disease which
typically involves hyperinsulinaemia and dyslipidaemia in addition to
the diagnostic characteristic of hyperglycaemia. In order to investi-
gate whether exposure to hyperglycaemia was sufficient to eliminate
protection by exosomes, we cultured HUVECs in medium containing
20 mM glucose, or an iso-osmotic control using mannitol. Mannitol
did not adversely affect protection afforded by exosomes, resulting in
29  4% cell death (P < 0.001 versus vehicle). In contrast, exo-
somes from cells in hyperglycaemic conditions were not protective
(39  2% cell death, N = 6; Fig. 4C).
We previously demonstrated that HSP70 localized on the surface
of exosomes can induce cardioprotection by signalling to TLR4 [9].
Hyperglycaemic conditions can cause the direct, non-enzymatic gly-
cation of proteins and modify their function, contributing to the devel-
opment of diabetes [16]. We, therefore, investigated the hypothesis
that high glucose conditions inactivated exosomal HSP70. Since exo-
somes are unstable when incubated for longer than 24 hrs [17], we
tested this hypothesis using pure, recombinant HSP70. We first con-
firmed that low concentrations of HSP70 are cardioprotective in our
model (Figs 5A, S5). Protection was determined to be optimal at
1 ng/ml (data not shown). In accordance with our previously identi-
fied pathway of protection, TAK242, an inhibitor of TLR4 signalling,
Fig. 3 Content of exosome marker pro-
teins CD81 and HSP70 in exosomes iso-
lated from rats (A and B), or HUVECs (C).
Markers were measured using an ELISA-
based ‘DELFIA’ assay (see methods).
N = 5 (A and B) or 4 (C). *P < 0.05. (D)
Quantitative immunostaining of levels of
the cmHSP70.1 epitope of HSP70 deter-
mined by a flow cytometry-based assay of
exosomes isolated from non-diabetic rats
and GK rats (N = 4). Statistical compar-
ison was by t-test (A, B, D), or ANOVA (C).
Fig. 4 Exosomes from diabetic rats or humans or from endothelial cells cultured under hyperglycaemic conditions were unable to protect primary
adult cardiomyocytes from death after hypoxia and reoxygenation. Cardiomyocytes were exposed to 108/ml exosomes from non-diabetic or GK rats
(A), non-diabetic or diabetic patients, (B), or 107/ml exosomes from HUVECs cultured in 20 mM glucose (gluc) or 20 mM mannitol (man). (C). The
cardioprotective agent, insulin was used as a positive control in each case. Cell death was assessed by propidium iodide staining. N = 5(A), 3(B) or
6 (C) independent experiments. Statistical comparison was by repeated measures ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns = non-significant
in the comparisons indicated.
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blocked protection (Fig. 5A). Pre-incubation of HSP70 in 20 mM glu-
cose for 7 days did not affect its ability to protect the cells against
hypoxia and reoxygenation (Fig. 5A). A sample treated with mannitol
was included as a non-reactive control. Modification of arginine to
argpyrimidine is one of the most common products of protein glyca-
tion, and HSP70 is susceptible to argpyrimidine modification in cer-
tain conditions [18]. However, in our hand, no argpyrimidine could be
detected by Western blot analysis of HSP70 after incubation with
20 mM glucose (Fig. 5B). In contrast, in a control sample of HSP70
incubated with 20 mM methyl glyoxyl, all of the HSP70 was modified
and it apparently aggregated, resulting in a diffuse and slowly migrat-
ing band near the top of the gel (Fig. 5B).
To determine whether diabetic exosomes are capable of activat-
ing cardioprotective kinase pathways, primary cardiomyocytes were
treated with exosomes purified from non-diabetic or diabetic rats
for 5 min. before harvesting and measuring kinase phosphorylation
by Western blot analysis. In contrast to the significant increase in
Erk1/2 and Hsp27 phosphorylation induced by non-diabetic exo-
somes, no increase in phosphorylation of either protein was
detected after treatment with exosomes from GK rats (N = 4;
Fig 6A–C).
Finally, it was important to establish whether exosomes from a
healthy individual could be used to protect cardiomyocytes coming
from a diabetic individual. To this end, we isolated cardiomyocytes
from adult GK rats. Exposure to hypoxia and reoxygenation signifi-
cantly increased cell death from 24  1% to 63  4% (P < 0.001;
Figs 7, S6). Pre-treatment with exosomes that had been isolated from
control rats without diabetes significantly reduced cell death to
29  3% (P < 0.001), which was a similar degree of protection as
the positive control of insulin, which reduced death to 35  5%
(P < 0.001; N = 4; Fig. 7).
Discussion
Exosomes have been suggested to mediate some of the beneficial
paracrine effects of stem cells in protecting the heart against IR injury
and have also been proposed as potential cardioprotective agents in
their own right [5, 19]. However, this property does not appear to be
restricted to exosomes from stem cells, since, as we previously
demonstrated, purified plasma exosomes are able to protect primary
cardiomyocytes, isolated perfused rat hearts and the heart in vivo
Fig. 5 Altered levels of exosomal HSP70
or its glycation do not appear to explain
the loss of cardioprotection. (A) Car-
diomyocytes were treated with 1 ng/ml
HSP70 that had been incubated 7 days in
20 mM glucose or 20 mM mannitol, prior
to exposure to hypoxia and reoxygenation
injury. Cell death was assessed by propid-
ium iodide staining. TAK242 is an inhibitor
of TLR4 signalling. (B) Western blot anal-
ysis of HSP70 treated as indicated, and
probed using antibodies against HSP70 or
the glycation end-product, argpyrimidine.
N = 4 independent experiments. Results
were compared by repeated measures
ANOVA. ***P < 0.001; ns = non-significant.
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against IR injury [9]. Similarly, exosomes secreted by cardiomyocytes
overexpressing HSP20 appear to improve cardiac function and angio-
genesis in diabetic mice [20]. Here, we demonstrate that the ability of
exosomes to activate a cardioprotective signalling pathway is
impaired by diabetes in both rats and humans. Hyperglycaemia
appears to be important in this effect as endothelial cells cultured in
high glucose produced exosomes that were no longer cardioprotec-
tive. Despite their being significantly more HSP70 on exosomes from
diabetic rats compared to non-diabetic rats, only exosomes from
non-diabetic rats were capable of signalling to ERK1/2 and HSP27.
We were unable to determine the reason for loss of protection by dia-
betic exosomes, but glycation of HSP70 is unlikely to be involved.
Most interestingly, in terms of developing exosomes as a potential
therapeutic agent, exosomes from a non-diabetic rat retained the abil-
ity to protect cardiomyocytes from a diabetic rat.
Why are exosomes from control blood
protective?
The physiological significance of the observation that endogenous
exosomes from unstimulated rats or humans are cardioprotective
remains unclear. Importantly, the observation that only exosomes
from non-diabetic rats or humans are protective, greatly strength-
ens the interpretation that protection is not an artefact of their iso-
lation and purification. We speculate that exosomes exert a
continual ‘tonic’ cardioprotective stimulus on the heart that may be
modified in response to stress. Indeed, application of an ischaemic
preconditioning stimulus to the limb (‘remote ischaemic precondi-
tioning’, or RIPC) increases the number of exosomes or extracellu-
lar vesicles in the blood of humans and rats [9, 21]. However, the
extent to which this increase in exosome number actually mediates
the cardioprotective benefits of RIPC in vivo remains unclear [9,
19, 21]. On the other hand, if exosomes do contribute to RIPC,
then our data would suggest that defective exosomal signalling
might contribute to the relative difficulty of protecting the diabetic
heart using RIPC [22, 23]. Future work will investigate the contri-
bution of different blood and vascular cell types (inflammatory
cells, platelets, endothelial cells, erythrocytes, etc) to the protection
observed with plasma exosomes).
What is the effect of diabetes on exosomes?
Diabetic conditions did not significantly alter the diameter of exo-
somes, according to our measurements by NTA and electron micro-
scopy. Interestingly, however, there was a consistent trend towards
increased diameter in both rat and human diabetic exosomes when
analysed by electron microscopy. As, in contrast to NTA, exosomes
must be dried for this type of analysis, it is possible this reflects an
underlying difference in lipid structure and ‘collapsibility’, but this is
highly speculative at this stage.
The significant increase in exosome marker proteins CD81 and
HSP70 in exosomes from diabetic rats suggests an overall increase in
exosome quantity in the setting of diabetes. Such an increase was not
detected by NTA, which may reflect the relatively low precision of this
method. In our hands, we have found that concentration determined
by NTA has a relatively high coefficient of variation of ~10%, which
matches published studies [24]. In comparison, ELISA-based meth-
ods are typically more precise. Despite the possible increase in exo-
some quantity in the blood, the diabetic exosomes were not
protective, suggesting they have been modified or damaged in some
way. Furthermore, despite the increase in total exosomal HSP70, the
cmHsp70.1 epitope of HSP70 was not elevated, suggesting that the
epitope may have been masked, modified or damaged to some extent.
A recent publication demonstrated that gestational diabetes mellitus
stimulates an increase in the release of exosomes from the placenta
during gestation [25]. The exosomes were found to significantly
increase the release of proinflammatory cytokines from endothelial
cells [25].
Why does high glucose cause loss of protection?
Cardiomyocytes respond rapidly to the interaction of exosomal
HSP70 with sarcolemmal TLR4 by activating the ERK1/2 cardiopro-
tective pathway, and phosphorylation of HSP27 [9]. Here, we found
that exosomes from diabetic rats no longer activated this pathway
in vitro. Glucose and other sugars can non-enzymatically modify pro-
teins covalently by a process of glycation, and this reaction is acceler-
ated under conditions of hyperglycaemia, as is present in diabetic
blood [16]. Such glycation can inactivate proteins and contributes to
Fig. 6 Phosphorylation of ERK1/2 and of
HSP27 was significantly increased in rat
cardiomyocytes treated for 5 min. with
108/ml exosomes from non-diabetic rats,
but not with those treated with exosomes
from GK rats (N = 4) (A–C). Fold increase
was compared by t-test. *P < 0.05.
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diabetic complications including retinopathy, nephropathy, neuropa-
thy and arterial abnormalities [16]. HSP70 has previously been identi-
fied as being susceptible to glycation, and this can cause a loss of its
protein chaperone enzymatic activity [26]. However, in our experi-
ments, in vitro exposure to high glucose did not cause a detectable
change in glycation of HSP70. It remains possible that hypergly-
caemia affects other aspects of exosomal structure or function yet to
be determined. Given our results, it is possible that diabetes and
hyperglycaemia could also impair other signalling roles that have
been ascribed to exosomes in various tissues and the vasculature [8,
27].
Surprisingly, we were not able to detect HSP70 on HUVEC
exosomes by immunoassay. This would appear to indicate that
HUVEC exosome induce protection by a separate mechanism, but
one that is also impaired by hyperglycaemia. Interestingly, brief
culture in high glucose conditions has also been shown to
impair the ability of apoptotic microvesicles released from human
endothelial cells to repair endothelium when administered to mice
[28]. In this case, the mechanism was reported to involve a
decrease in exosomal miR-126 content [28]. Exosomes from var-
ious sources have also been shown to stimulate angiogenesis.
On the other hand, exosomes from GK rat cardiomyocytes were
found to inhibit the proliferation, migration and tube formation of
a cardiac endothelial cell line [29]. This was reportedly via a
mechanism involving exosomal transfer of miR-320, although
lower miR-126 levels were also detected in this study [29]. In
contrast to endothelial cells, cardiomyocytes take up relatively
few exosomes [9]. Furthermore, a 30 min. exposure to exosomes
is far too short for sufficient miRNA to enter cells and poten-
tially affect protein levels significantly. These factors make a role
for exosomal miRNA in loss of protection of cardiomyocytes
unlikely.
Protection of diabetic hearts using non-diabetic
exosomes
Our experiments demonstrate that cardioprotective signalling can
be activated in cardiomyocytes from diabetic rats using exosomes
from non-diabetic animals. A limitation of these studies is that we
have not demonstrated that non-diabetic exosomes are capable of
protecting the hearts of diabetic rats when administered acutely
in vivo. Additionally, other extracellular vesicles such as microvesi-
cles can potentially co-purify with exosomes isolated by differential
centrifugation, and these may mediate some of the protective effect.
However, our data support the idea that exosomes harvested from
blood plasma or a suitable cellular source (such as the endothelial
cells used here, stem cells [6], or cultured cardiomyocytes overex-
pressing HSP20 [20] as proposed by others [30]), may therefore
represent a cardioprotective agent with the novel and desirable
property that it is effective in the setting of diabetes [31]. Important
questions remain before clinical translation can be attempted,
including the pharmacodynamics and pharmacokinetics of exo-
somes in vivo. Another important challenge will be the development
of robust techniques for large-scale purification of GMP-quality,
validated exosomes [7].
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Figure S1 The number of exosome particles per lg protein in sam-
ples from non-diabetic and diabetic GK rats.
Figure S2 Representative images of normoxic cardiomyocytes,
and cardiomyocytes treated with vehicle, exosomes from GK
or non-diabetic rats, or insulin, before hypoxia and reoxy-
genation.
Figure S3 Representative images of cardiomyocytes treated
with vehicle, exosomes from diabetic or non-diabetic humans,
before hypoxia and reoxygenation.
Figure S4 Representative images of normoxic cardiomyocytes, and
cardiomyocytes treated with exosomes from HUVEC in normoxic or
high glucose conditions before hypoxia and reoxygenation.
Figure S5 Representative images of normoxic cardiomyocytes
treated with recombinant HSP70 and cardiomyocytes treated with
recombinant HSP70 or insulin before hypoxia and reoxygenation.
Figure S6 Representative images of normoxic GK cardiomy-
ocytes, and GK cardiomyocytes treated with exosomes insulin
before hypoxia and reoxygenation.
References
1. ElBardissi AW, Aranki SF, Sheng S, et al.
Trends in isolated coronary artery bypass
grafting: an analysis of the Society of Tho-
racic Surgeons adult cardiac surgery data-
base. J Thorac Cardiovasc Surg. 2012; 143:
273–81.
2. Tsang A, Hausenloy DJ, Mocanu MM, et al.
Preconditioning the diabetic heart: the
importance of Akt phosphorylation. Dia-
betes. 2005; 54: 2360–4.
3. Lecour S, Bøtker HE, Condorelli G, et al. ESC
working group cellular biology of the heart:
position paper: improving the preclinical
assessment of novel cardioprotective thera-
pies. Cardiovasc Res. 2014; 104: 399–411.
4. McGuire DK, Emanuelsson H, Granger CB,
et al. Influence of diabetes mellitus on clini-
cal outcomes across the spectrum of acute
coronary syndromes. Findings from the
GUSTO-IIb study. GUSTO IIb Investigators.
Eur Heart J. 2000; 21: 1750–8.
5. Yellon DM, Davidson SM. Exosomes:
nanoparticles involved in cardioprotection?
Circ Res. 2014; 114: 325–32.
6. Kishore R, Khan M. More Than Tiny Sacks:
stem Cell Exosomes as Cell-Free Modality
for Cardiac Repair. Circ Res. 2016; 118:
330–43.
7. Lener T, Gimona M, Aigner L, et al. Apply-
ing extracellular vesicles based therapeutics
in clinical trials - an ISEV position paper. J
Extracell Vesicles. 2015; 4: 30087.
8. Lawson C, Vicencio JM, Yellon DM, et al.
Microvesicles and exosomes: new players in
metabolic and cardiovascular disease. J
Endocrinol. 2016; 228: R57–71.
9. Vicencio JM, Yellon DM, Sivaraman V,
et al. Plasma exosomes protect the
myocardium from ischemia-reperfusion
injury. J Am Coll Cardiol. 2015; 65: 1525–
36.
10. Hausenloy DJ, Yellon DM. New directions
for protecting the heart against ischaemia-
reperfusion injury: targeting the Reperfusion
Injury Salvage Kinase (RISK)-pathway. Car-
diovascRes. 2004; 61: 448–60.
11. Davidson SM, Hausenloy D, Duchen MR,
et al. Signalling via the reperfusion injury
signalling kinase (RISK) pathway links clo-
sure of the mitochondrial permeability tran-
sition pore to cardioprotection. Int J
Biochem Cell Biol. 2006; 38: 414–9.
12. van der Pol E, Boing AN, Gool EL, et al.
Recent developments in the nomenclature,
presence, isolation, detection and clinical
impact of extracellular vesicles. J Thromb
Haemost. 2016; 14: 48–56.
13. Thery C, Amigorena S, Raposo G, et al. Iso-
lation and characterization of exosomes
from cell culture supernatants and biological
fluids. Curr Protoc Cell Biol. 2006; Chapter
3: Unit 3 22.
14. Welton JL, Webber JP, Botos LA, et al.
Ready-made chromatography columns for
extracellular vesicle isolation from plasma. J
Extracell Vesicles. 2015; 4: 27269.
15. Stangl S, Gehrmann M, Riegger J, et al.
Targeting membrane heat-shock protein 70
(Hsp70) on tumors by cmHsp70.1 antibody.
Proc Natl Acad Sci USA. 2011; 108: 733–8.
16. Brownlee M. Advanced protein glycosylation
in diabetes and aging. Annu Rev Med. 1995;
46: 223–34.
17. Lorincz AM, Timar CI, Marosvari KA, et al.
Effect of storage on physical and functional
properties of extracellular vesicles derived
from neutrophilic granulocytes. J Extracell
Vesicles. 2014; 3: 25465.
18. Antognelli C, Gambelunghe A, Muzi G, et al.
Peroxynitrite-mediated glyoxalase I epigenetic
inhibition drives apoptosis in airway epithelial
cells exposed to crystalline silica via a novel
mechanism involving argpyrimidine-modified
Hsp70, JNK, and NF-kappaB. Free Radic Biol
Med. 2015; 84: 128–41.
19. Giricz Z, Varga ZV, Baranyai T, et al. Car-
dioprotection by remote ischemic precondi-
tioning of the rat heart is mediated by
extracellular vesicles. J Mol Cell Cardiol.
2014; 68: 75–8.
20. Wang X, Gu H, Huang W, et al. Hsp20-
Mediated Activation of Exosome Biogenesis
in Cardiomyocytes Improves Cardiac Func-
tion and Angiogenesis in Diabetic Mice. Dia-
betes. 2016; 65: 3111–28.
21. Jeanneteau J, Hibert P, Martinez MC, et al.
Microparticle release in remote ischemic
conditioning mechanism. Am J Physiol
Heart Circ Physiol. 2012; 303: H871–7.
22. Sivaraman V, Hausenloy DJ, Wynne AM,
et al. Preconditioning the diabetic human
myocardium. J Cell Mol Med. 2010; 14:
1740–6.
23. Jensen RV, Stottrup NB, Kristiansen SB,
et al. Release of a humoral circulating car-
dioprotective factor by remote ischemic pre-
conditioning is dependent on preserved
neural pathways in diabetic patients. Basic
Res Cardiol. 2012; 107: 285.
24. Hole P, Sillence K, Hannell C, et al. Inter-
laboratory comparison of size measure-
ments on nanoparticles using nanoparticle
tracking analysis (NTA). J Nanopart Res.
2013; 15: 2101.
25. Salomon C, Scholz-Romero K, Sarker S,
et al. Gestational Diabetes Mellitus Is Asso-
ciated With Changes in the Concentration
and Bioactivity of Placenta-Derived Exo-
somes in Maternal Circulation Across Gesta-
tion. Diabetes. 2016; 65: 598–609.
26. Takino J, Kobayashi Y, Takeuchi M. The
formation of intracellular glyceraldehyde-
derived advanced glycation end-products
10 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
and cytotoxicity. J Gastroenterol. 2010; 45:
646–55.
27. Lo Cicero A, Stahl PD, Raposo G. Extracel-
lular vesicles shuffling intercellular mes-
sages: for good or for bad. Curr Opin Cell
Biol. 2015; 35: 69–77.
28. Jansen F, Yang X, Hoelscher M, et al.
Endothelial microparticle-mediated transfer
of MicroRNA-126 promotes vascular
endothelial cell repair via SPRED1 and is
abrogated in glucose-damaged endothelial
microparticles. Circulation. 2013; 128:
2026–38.
29. Wang X, Huang W, Liu G, et al. Cardiomy-
ocytes mediate anti-angiogenesis in type 2
diabetic rats through the exosomal transfer
of miR-320 into endothelial cells. J Mol Cell
Cardiol. 2014; 74: 139–50.
30. Sahoo S, Emanueli C. Exosomes in Diabetic
Cardiomyopathy: the Next-Generation Thera-
peutic Targets? Diabetes. 2016; 65: 2829–31.
31. Davidson SM, Takov K, Yellon DM. Exo-
somes and Cardiovascular Protection. Car-
diovasc Drugs Ther. 2017; 31: 77–86.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
11
J. Cell. Mol. Med. Vol XX, No X, 2017
